Your search returned over 250 studies. The top 250 studies are being displayed. Please use additional keywords or decrease the search distance. Get alerts for new studies
- Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Conditions: Brain and Central Nervous System Tumors
Location: Kingman, Kansas
- Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Conditions: Brain and Central Nervous System Tumors
Location: Newton, Kansas
- Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Conditions: Brain and Central Nervous System Tumors
Location: Pratt, Kansas
- Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Conditions: Brain and Central Nervous System Tumors
Location: Wellington, Kansas
- Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Conditions: Brain and Central Nervous System Tumors
Location: Wichita, Kansas
- Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Conditions: Brain and Central Nervous System Tumors
Location: Wichita, Kansas
- Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Conditions: Brain and Central Nervous System Tumors
Location: Wichita, Kansas
- Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Conditions: Brain and Central Nervous System Tumors
Location: Wichita, Kansas
- Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Conditions: Brain and Central Nervous System Tumors
Location: Wichita, Kansas
- Pentostatin, Cyclophosphamide, and Rituximab Followed By Alemtuzumab in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leuke
Conditions: Leukemia
Location: Kingman, Kansas
- Pentostatin, Cyclophosphamide, and Rituximab Followed By Alemtuzumab in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leuke
Conditions: Leukemia
Location: Newton, Kansas
- Pentostatin, Cyclophosphamide, and Rituximab Followed By Alemtuzumab in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leuke
Conditions: Leukemia
Location: Pratt, Kansas
- Pentostatin, Cyclophosphamide, and Rituximab Followed By Alemtuzumab in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leuke
Conditions: Leukemia
Location: Wellington, Kansas
- Pentostatin, Cyclophosphamide, and Rituximab Followed By Alemtuzumab in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leuke
Conditions: Leukemia
Location: Wichita, Kansas
- Pentostatin, Cyclophosphamide, and Rituximab Followed By Alemtuzumab in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leuke
Conditions: Leukemia
Location: Wichita, Kansas
- Pentostatin, Cyclophosphamide, and Rituximab Followed By Alemtuzumab in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leuke
Conditions: Leukemia
Location: Wichita, Kansas
- Pentostatin, Cyclophosphamide, and Rituximab Followed By Alemtuzumab in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leuke
Conditions: Leukemia
Location: Wichita, Kansas
- Pentostatin, Cyclophosphamide, and Rituximab Followed By Alemtuzumab in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leuke
Conditions: Leukemia
Location: Wichita, Kansas
- Mindfulness Relaxation Compared With Relaxing Music and Standard Symptom Management Education in Treating Patients Who Are Undergoing Chemotherapy For
Conditions: Nausea and Vomiting - Unspecified Adult Solid Tumor, Protocol Specific
Location: Wichita, Kansas
- Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallo
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Peritoneal Cavity Cancer
Location: Kingman, Kansas
- Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallo
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Peritoneal Cavity Cancer
Location: Newton, Kansas
- Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallo
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Peritoneal Cavity Cancer
Location: Pratt, Kansas
- Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallo
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Peritoneal Cavity Cancer
Location: Wellington, Kansas
- Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallo
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Peritoneal Cavity Cancer
Location: Wichita, Kansas
- Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallo
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Peritoneal Cavity Cancer
Location: Wichita, Kansas
- Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallo
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Peritoneal Cavity Cancer
Location: Wichita, Kansas
- Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallo
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Peritoneal Cavity Cancer
Location: Wichita, Kansas
- Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallo
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Peritoneal Cavity Cancer
Location: Wichita, Kansas
- Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Conditions: Lymphoma
Location: Kingman, Kansas
- Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Conditions: Lymphoma
Location: Newton, Kansas
- Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Conditions: Lymphoma
Location: Pratt, Kansas
- Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Conditions: Lymphoma
Location: Wellington, Kansas
- Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Conditions: Lymphoma
Location: Wichita, Kansas
- Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Conditions: Lymphoma
Location: Wichita, Kansas
- Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Conditions: Lymphoma
Location: Wichita, Kansas
- Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Conditions: Lymphoma
Location: Wichita, Kansas
- Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Conditions: Lymphoma
Location: Wichita, Kansas
- Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Conditions: Leukemia
Location: Kingman, Kansas
- Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Conditions: Leukemia
Location: Newton, Kansas
- Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Conditions: Leukemia
Location: Pratt, Kansas
- Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Conditions: Leukemia
Location: Wellington, Kansas
- Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Conditions: Leukemia
Location: Wichita, Kansas
- Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Conditions: Leukemia
Location: Wichita, Kansas
- Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Conditions: Leukemia
Location: Wichita, Kansas
- Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Conditions: Leukemia
Location: Wichita, Kansas
- Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Conditions: Leukemia
Location: Wichita, Kansas
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Kingman, Kansas
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Newton, Kansas
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Pratt, Kansas
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Wellington, Kansas
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Wichita, Kansas
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Wichita, Kansas
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Wichita, Kansas
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Wichita, Kansas
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Wichita, Kansas
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Kingman, Kansas
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Newton, Kansas
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Pratt, Kansas
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Wellington, Kansas
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Wichita, Kansas
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Wichita, Kansas
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Wichita, Kansas
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Wichita, Kansas
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Wichita, Kansas
- Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors
Conditions: Brain and Central Nervous System Tumors - Cognitive/Functional Effects - Fatigue - Metastatic Cancer - Psychosocial Effects of Cancer and Its Treatment - Radiation Toxicity
Location: Wichita, Kansas
- Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors
Conditions: Brain and Central Nervous System Tumors - Cognitive/Functional Effects - Fatigue - Metastatic Cancer - Psychosocial Effects of Cancer and Its Treatment - Radiation Toxicity
Location: Wichita, Kansas
- Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors
Conditions: Brain and Central Nervous System Tumors - Cognitive/Functional Effects - Fatigue - Metastatic Cancer - Psychosocial Effects of Cancer and Its Treatment - Radiation Toxicity
Location: Wichita, Kansas
- Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors
Conditions: Brain and Central Nervous System Tumors - Cognitive/Functional Effects - Fatigue - Metastatic Cancer - Psychosocial Effects of Cancer and Its Treatment - Radiation Toxicity
Location: Wichita, Kansas
- Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors
Conditions: Brain and Central Nervous System Tumors - Cognitive/Functional Effects - Fatigue - Metastatic Cancer - Psychosocial Effects of Cancer and Its Treatment - Radiation Toxicity
Location: Wichita, Kansas
- Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors
Conditions: Brain and Central Nervous System Tumors - Cognitive/Functional Effects - Fatigue - Metastatic Cancer - Psychosocial Effects of Cancer and Its Treatment - Radiation Toxicity
Location: Wichita, Kansas
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Anthony, Kansas
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Kingman, Kansas
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Newton, Kansas
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Pratt, Kansas
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Wellington, Kansas
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Wichita, Kansas
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Wichita, Kansas
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Wichita, Kansas
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Wichita, Kansas
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Wichita, Kansas
- Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Canc
Conditions: Small Intestine Cancer
Location: Kingman, Kansas
- Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Canc
Conditions: Small Intestine Cancer
Location: Newton, Kansas
- Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Canc
Conditions: Small Intestine Cancer
Location: Pratt, Kansas
- Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Canc
Conditions: Small Intestine Cancer
Location: Wellington, Kansas
- Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Canc
Conditions: Small Intestine Cancer
Location: Wichita, Kansas
- Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Canc
Conditions: Small Intestine Cancer
Location: Wichita, Kansas
- Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Canc
Conditions: Small Intestine Cancer
Location: Wichita, Kansas
- Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Canc
Conditions: Small Intestine Cancer
Location: Wichita, Kansas
- Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Canc
Conditions: Small Intestine Cancer
Location: Wichita, Kansas
- Erlotinib and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Kingman, Kansas
- Erlotinib and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Newton, Kansas
- Erlotinib and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Pratt, Kansas
- Erlotinib and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Wellington, Kansas
- Erlotinib and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Wichita, Kansas
- Erlotinib and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Wichita, Kansas
- Erlotinib and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Wichita, Kansas
- Erlotinib and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Wichita, Kansas
- Erlotinib and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Wichita, Kansas
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Anthony, Kansas
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Kingman, Kansas
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Newton, Kansas
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Pratt, Kansas
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Wellington, Kansas
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Wichita, Kansas
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Wichita, Kansas
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Wichita, Kansas
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Wichita, Kansas
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Wichita, Kansas
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Wichita, Kansas
- Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Malignant Tumor of Peritoneum
Location: Kingman, Kansas
- Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Malignant Tumor of Peritoneum
Location: Newton, Kansas
- Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Malignant Tumor of Peritoneum
Location: Pratt, Kansas
- Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Malignant Tumor of Peritoneum
Location: Wellington, Kansas
- Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Malignant Tumor of Peritoneum
Location: Wichita, Kansas
- Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Malignant Tumor of Peritoneum
Location: Wichita, Kansas
- Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Malignant Tumor of Peritoneum
Location: Wichita, Kansas
- Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Malignant Tumor of Peritoneum
Location: Wichita, Kansas
- Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Malignant Tumor of Peritoneum
Location: Wichita, Kansas
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Wichita, Kansas
- Combination Chemotherapy Followed By Docetaxel or Ixabepilone in Treating Patients Who Have Undergone Surgery for Nonmetastatic Breast Cancer
Conditions: Breast Cancer
Location: Wichita, Kansas
- Safety of Sports for Patients With Implantable Cardioverter-Defibrillators
Conditions: Patients With ICD's Who Are Participating in Sports.
Location: Wichita, Kansas
- Azacitidine and Gemtuzumab in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Conditions: Leukemia
Location: Kingman, Kansas
- Azacitidine and Gemtuzumab in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Conditions: Leukemia
Location: Newton, Kansas
- Azacitidine and Gemtuzumab in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Conditions: Leukemia
Location: Pratt, Kansas
- Azacitidine and Gemtuzumab in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Conditions: Leukemia
Location: Wellington, Kansas
- Azacitidine and Gemtuzumab in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Conditions: Leukemia
Location: Wichita, Kansas
- Azacitidine and Gemtuzumab in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Conditions: Leukemia
Location: Wichita, Kansas
- Azacitidine and Gemtuzumab in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Conditions: Leukemia
Location: Wichita, Kansas
- Azacitidine and Gemtuzumab in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Conditions: Leukemia
Location: Wichita, Kansas
- Azacitidine and Gemtuzumab in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Conditions: Leukemia
Location: Wichita, Kansas
- Azacitidine and Gemtuzumab in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Conditions: Leukemia
Location: Wichita, Kansas
- Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemot
Conditions: Lung Cancer
Location: Kingman, Kansas
- Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemot
Conditions: Lung Cancer
Location: Newton, Kansas
- Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemot
Conditions: Lung Cancer
Location: Pratt, Kansas
- Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemot
Conditions: Lung Cancer
Location: Wellington, Kansas
- Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemot
Conditions: Lung Cancer
Location: Wichita, Kansas
- Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemot
Conditions: Lung Cancer
Location: Wichita, Kansas
- Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemot
Conditions: Lung Cancer
Location: Wichita, Kansas
- Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemot
Conditions: Lung Cancer
Location: Wichita, Kansas
- Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemot
Conditions: Lung Cancer
Location: Wichita, Kansas
- Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Conditions: Malignant Mesothelioma
Location: Kingman, Kansas
- Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Conditions: Malignant Mesothelioma
Location: Newton, Kansas
- Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Conditions: Malignant Mesothelioma
Location: Pratt, Kansas
- Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Conditions: Malignant Mesothelioma
Location: Wellington, Kansas
- Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Conditions: Malignant Mesothelioma
Location: Wichita, Kansas
- Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Conditions: Malignant Mesothelioma
Location: Wichita, Kansas
- Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Conditions: Malignant Mesothelioma
Location: Wichita, Kansas
- Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Conditions: Malignant Mesothelioma
Location: Wichita, Kansas
- Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Conditions: Malignant Mesothelioma
Location: Wichita, Kansas
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Kingman, Kansas
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Newton, Kansas
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Pratt, Kansas
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Wellington, Kansas
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Wichita, Kansas
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Wichita, Kansas
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Wichita, Kansas
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Wichita, Kansas
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Wichita, Kansas
- Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Kingman, Kansas
- Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Newton, Kansas
- Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Pratt, Kansas
- Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Wellington, Kansas
- Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Wichita, Kansas
- Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Wichita, Kansas
- Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Wichita, Kansas
- Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Wichita, Kansas
- Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Wichita, Kansas
- Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Conditions: Anemia - Leukemia - Myelodysplastic Syndromes
Location: Wichita, Kansas
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Kingman, Kansas
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Newton, Kansas
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Pratt, Kansas
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Wellington, Kansas
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Wichita, Kansas
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Wichita, Kansas
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Wichita, Kansas
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Wichita, Kansas
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Wichita, Kansas
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Kingman, Kansas
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Newton, Kansas
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Pratt, Kansas
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Wellington, Kansas
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Wichita, Kansas
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Wichita, Kansas
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Wichita, Kansas
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Wichita, Kansas
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Wichita, Kansas
- Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Wichita, Kansas
- Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Wichita, Kansas
- Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Kingman, Kansas
- Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Newton, Kansas
- Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Pratt, Kansas
- Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Wellington, Kansas
- Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Wichita, Kansas
- Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Wichita, Kansas
- Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Wichita, Kansas
- Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Wichita, Kansas
- Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Wichita, Kansas
- Safety and Efficacy of F2695 SR in Major Depressive Disorder
Conditions: Major Depressive Disorder
Location: Wichita, Kansas
- Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Au
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Kingman, Kansas
- Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Au
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Newton, Kansas
- Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Au
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Pratt, Kansas
- Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Au
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Wellington, Kansas
- Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Au
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Wichita, Kansas
- Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Au
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Wichita, Kansas
- Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Au
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Wichita, Kansas
- Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Au
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Wichita, Kansas
- Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Au
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Wichita, Kansas
- Insulin Resistance Intervention After Stroke Trial
Conditions: Stroke - Myocardial Infarction - Diabetes
Location: Wichita, Kansas
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer
Conditions: Prostate Cancer
Location: Hutchinson, Kansas
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Hutchinson, Kansas
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Kingman, Kansas
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: McPherson, Kansas
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Newton, Kansas
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Pratt, Kansas
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Wellington, Kansas
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Wichita, Kansas
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Wichita, Kansas
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Wichita, Kansas
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Wichita, Kansas
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Wichita, Kansas
- Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer
Conditions: Prostate Cancer
Location: Hutchinson, Kansas
- A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis
Conditions: Atopic Dermatitis
Location: Wichita, Kansas
- Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
Conditions: Leukemia
Location: Kingman, Kansas
- Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
Conditions: Leukemia
Location: Newton, Kansas
- Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
Conditions: Leukemia
Location: Pratt, Kansas
- Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
Conditions: Leukemia
Location: Wellington, Kansas
- Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
Conditions: Leukemia
Location: Wichita, Kansas
- Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
Conditions: Leukemia
Location: Wichita, Kansas
- Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
Conditions: Leukemia
Location: Wichita, Kansas
- Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
Conditions: Leukemia
Location: Wichita, Kansas
- Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
Conditions: Leukemia
Location: Wichita, Kansas
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Hutchinson, Kansas
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Kingman, Kansas
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: McPherson, Kansas
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Newton, Kansas
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Pratt, Kansas
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Wellington, Kansas
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Wichita, Kansas
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Wichita, Kansas
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Wichita, Kansas
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Wichita, Kansas
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Wichita, Kansas
- Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Head and Neck Cancer
Location: Kingman, Kansas
- Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Head and Neck Cancer
Location: McPherson, Kansas
- Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Head and Neck Cancer
Location: Newton, Kansas
- Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Head and Neck Cancer
Location: Pratt, Kansas
- Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Head and Neck Cancer
Location: Wellington, Kansas
- Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Head and Neck Cancer
Location: Wichita, Kansas
- Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Head and Neck Cancer
Location: Wichita, Kansas
- Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Head and Neck Cancer
Location: Wichita, Kansas
|